| Schedule of Liabilities Measured on Recurring Basis |
The following table presents our assets and liabilities measured at fair value on a recurring basis at December 31, 2021: | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements at | | | | December 31, 2021 | | Total | | Quoted Prices in Active Markets
(Level 1) | | Significant Other Observable Inputs
(Level 2) | | Significant Unobservable Inputs
(Level 3) | | Assets: | | | | | | | | | Tonogold common shares | $ | 910,558 | | | $ | 910,558 | | | $ | — | | | $ | — | | | Tonogold note receivable | 7,255,000 | | | — | | | — | | | 7,255,000 | | | LPB derivative asset | 342,000 | | | — | | | 342,000 | | | — | | | Other equity securities | 15,260 | | | 15,260 | | | — | | | — | | | Total assets measured at fair value | $ | 8,522,818 | | | $ | 925,818 | | | $ | 342,000 | | | $ | 7,255,000 | | | | | | | | | | | Liabilities: | | | | | | | | | LINICO acquisition derivative liability | $ | (2,743,162) | | | $ | (2,743,162) | | | $ | — | | | $ | — | | | GenMat derivative | $ | (6,130,000) | | | $ | — | | | $ | (6,130,000) | | | $ | — | | | Total liabilities measured at fair value | $ | (8,873,162) | | | $ | (2,743,162) | | | $ | (6,130,000) | | | $ | — | |
The following table presents our assets and liabilities at December 31, 2020, which are measured at fair value on a recurring basis: | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements at | | | | December 31, 2020 | | Total | | Quoted Prices in Active Markets
(Level 1) | | Significant Other Observable Inputs
(Level 2) | | Significant Unobservable Inputs
(Level 3) | | Assets: | | | | | | | | | Tonogold common shares | $ | 3,939,558 | | | $ | 3,939,558 | | | $ | — | | | $ | — | | | Tonogold note receivable | 5,498,500 | | | — | | | — | | | 5,498,500 | | | MCU derivative asset | 265,127 | | | — | | | 265,127 | | | — | | | Other equity securities | 40,165 | | | — | | | 40,165 | | | — | | | Total assets measured at fair value | $ | 9,743,350 | | | $ | 3,939,558 | | | $ | 305,292 | | | $ | 5,498,500 | |
The following table presents our assets and liabilities measured at fair value on a recurring basis at March 31, 2022: | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements at | | | | March 31, 2022 | | Total | | Quoted Prices in Active Markets
(Level 1) | | Significant Other Observable Inputs
(Level 2) | | Significant Unobservable Inputs
(Level 3) | | Assets: | | | | | | | | | Tonogold common shares | $ | 1,100,293 | | | $ | 1,100,293 | | | $ | — | | | $ | — | | | Other equity securities | 7,449 | | | 7,449 | | | — | | | — | | | Total assets measured at fair value | $ | 1,107,742 | | | $ | 1,107,742 | | | $ | — | | | $ | — | | | | | | | | | | | Liabilities: | | | | | | | | | LINICO acquisition derivative liability | $ | (1,413,162) | | | $ | — | | | $ | (1,413,162) | | | $ | — | | | GenMat derivative liability | (4,990,000) | | | — | | | (4,990,000) | | | — | | | Total liabilities measured at fair value | $ | (6,403,162) | | | $ | — | | | $ | (6,403,162) | | | $ | — | |
The following table presents our assets and liabilities at December 31, 2021, which are measured at fair value on a recurring basis: | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements at | | | | December 31, 2021 | | Total | | Quoted Prices in Active Markets
(Level 1) | | Significant Other Observable Inputs
(Level 2) | | Significant Unobservable Inputs
(Level 3) | | Assets: | | | | | | | | | Tonogold common shares | $ | 910,559 | | | $ | 910,559 | | | $ | — | | | $ | — | | | Tonogold note receivable | 7,255,000 | | | — | | | — | | | 7,255,000 | | | MCU derivative asset | 342,000 | | | — | | | 342,000 | | | — | | | Other equity securities | 15,260 | | | 15,260 | | | — | | | — | | | Total assets measured at fair value | $ | 8,522,819 | | | $ | 925,819 | | | $ | 342,000 | | | $ | 7,255,000 | | | | | | | | | | | Liabilities: | | | | | | | | | LINICO acquisition derivative liability | $ | (2,743,162) | | | $ | — | | | $ | (2,743,162) | | | $ | — | | | GenMat derivative liability | (6,130,000) | | | — | | | (6,130,000) | | | — | | | Total liabilities measured at fair value | $ | (8,873,162) | | | $ | — | | | $ | (8,873,162) | | | $ | — | |
|
| Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation |
The following table provides reconciliation between the beginning and ending balance of investments measured at fair value on a recurring basis using significant unobservable inputs (Level 3). | | | | | | | | | | | | | 12/31/21 | | 12/31/20 | | Beginning Balance | $ | 5,498,500 | | | $ | 9,080,000 | | | Total change in fair value recognized in earnings | | | | | Tonogold convertible preferred shares | — | | | (2,544,000) | | | Tonogold contingent forward asset | — | | | 765,880 | | | Tonogold note receivable | (418,500) | | | (642,997) | | | (418,500) | | | (2,421,117) | | | Additions | | | | | Tonogold contingent forward asset | — | | | 1,232,952 | | | Tonogold note receivable | 2,175,000 | | | 6,141,497 | | | 2,175,000 | | | 7,374,449 | | | Transfers | | | | | Conversion of Tonogold convertible preferred shares to Tonogold common | — | | | (3,920,000) | | | Deductions: | | | | | Redemption of Tonogold convertible preferred shares | — | | | (2,616,000) | | | Settlement of Tonogold contingent forward asset | — | | | (1,998,832) | | | — | | | (4,614,832) | | | Ending balance | $ | 7,255,000 | | | $ | 5,498,500 | |
|